Discover the volumizer
designed to stimulate collagen
with results that last over 2 years*

Elaine: Age 40 (2.5 vials)  Christine: Age 39 (2 vials)  Veronica: Age 33 (4 vials)

*Clinical trial ended at 25 months

Actual Sculptra Aesthetic patients at 12 months

stimulates collagen for a natural look
Sculptra® Aesthetic is designed to stimulate collagen naturally.

The Underlying Causes Of Facial Aging¹⁻⁶

Collagen loss along with other subdermal processes of fat loss and fat pad migration is a key factor in the aging process.

As skin ages, the middle layer of skin (dermis) thins due to collagen loss, reducing the skin’s ability to retain elasticity (from elastin) and moisture (from hyaluronic acid).

Loss of elastin and hyaluronic acid results in skin that is:
- drier
- less supple
- less elastic
- thinner due to volume loss

Loss of volume in the subdermal tissues starts early in life and progresses, manifesting in these visible signs of aging including:
- wrinkles
- folds
- lines

In an exploratory study Sculptra® Aesthetic significantly grew collagen."³

In an exploratory single-arm, open-label study titled A Single-Arm Study for the Characterization of Human Tissue Response to Injectable Poly-L-lactic Acid 14 healthy subjects were administered injectable PLLA; punch biopsies at 3, 6 and 12 months were analyzed for qualitative and quantitative changes from baseline in collagen types I and III, and assessed for inflammatory response. Post hoc assessments at 12 months showed nominal collagen increases, (not statistically significant) but were hindered by technical difficulties. Results of this study in humans found statistically significant stimulation of collagen type I with no mild inflammatory response following administration of injectable PLLA.

In a separate study, nasolabial biopsies from a 55-year-old woman, 12 and 30 months after last treatment with Sculptra Aesthetic (injectable poly-L-lactic Acid).²

Figure 1. Histologic examination (original magnification x 400) exhibiting microparticles of PLLA at 12 months after last treatment, with adjacent aggregation of giant cells, histiocytes and collagen fibers.

Figure 2. Histologic examination (original magnification x 400) of the injected PLLA at 30 months after last treatment, showing the lack of PLLA microparticles and the abundance of collagen fibers.

A = Collagen Type 1
B = Sculptra Aesthetic

NEW COLLAGEN GROWTH AT 12 AND 30 MONTHS

66% of new collagen growth seen at 3 months above baseline

Figure 1: 12 Months
Figure 2: 30 Months
Sculptra® Aesthetic gradually volumizes, providing optimal and natural correction

- Sculptra Aesthetic (n=116)
- CosmoPlast® collagen (n=117)

*Sculptra® Aesthetic (injectable poly-l-lactic acid) vs. 2004 standard of care*

**Investigators used a 5-point scale (4=excellent improvement, 3=much improved, 2=improved, 1=no change, 0=worse) for global evaluations.**

**Randomized, evaluator-blinded, parallel-group, multicenter study of 233 patients.**

High levels of patient satisfaction

80.0% of patients still rated their results as “good to excellent” at 25 months**

*Based upon good, very good, and excellent scores.*

86.3% of patients still showed overall improvement at 25 months after treatment, as rated by investigators**

*Randomized, evaluator-blinded, parallel-group, multicenter study of 233 patients.*

P<0.001 from baseline for all Sculptra Aesthetic follow-up timepoints.

**Clinical trial ended at 25 months.**

Sculptra.ca
Sculptra® Aesthetic stimulates natural collagen to provide facial volume.

Vivian: 53 Years Old (4 vials) 12 months

Individual results and treatment regimens may vary (all photos unretouched)

Left Cheek:
Volume change +7.065 cc

Right Cheek:
Volume change +8.323 cc

This image is an overlay of a baseline and 12 month post treatment 3D model. The space between the model illustrates the increase in volume. 3D images were captured using a VECTRA® imaging system (Canfield Imaging Systems, Fairfield NJ)
Sculptra® Aesthetic allows you to create a natural

Individual results and treatment regimens may vary (all photos unretouched)

**JB:** 40 Years Old (4 vials)  5 months

**Franca:** 42 Years Old (5 vials)  25 months

Individual results may vary
Elissa: 49 Years Old (5 vials) 25 months

Pam: 63 Years Old (6 vials) 9 months

Individual results may vary
Individual results and treatment regimens may vary (all photos unretouched)

Terry: 57 Years Old (7 vials) 9 months

Lisa: 50 Years Old (1 vial) 1 month

**Sculptra**

- **Indication:** Sculptra®  is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging.
- **Important Safety Information:** Immediately following an injection session with Sculptra®, redness, swelling and/or bruising may occur at the injection site. These typically resolve in hours to one week after the injection. Hematoma (blood spot under the skin) may also occur, typically resolving in hours to about two weeks.
- **Treatment with Sculptra®** can also result in small papules in the treatment area. These subcutaneous (beneath the skin) papules are typically not visible and asymptomatic, and may be noticed only upon pressing on the treatment area. Visible nodules, sometimes with redness or colour change to the skin, have also been reported.
- **Long-term safety and effectiveness of Sculptra®** beyond two years have not been studied in controlled clinical trials.
- There is a possible risk of eliciting an inflammatory reaction at the implant site. This also applies if Sculptra® is administered before the skin has healed completely after such a procedure.
- **Safety results in a key clinical trial (physician-reported events)**
  - Occurrence of physician-reported papules**:10**,²
    - 8.6% at 13 months; 1.9% at 25 months
  - Occurrence of physician-reported nodules**:10**,²
    - 8.6% at 13 months; 0.9% at 25 months
  - Occurrence of injection site pain recalled from patient diaries**:10**,²
    - 9.5% at 13 months; 0.9% at 25 months
  - Papules and nodules were typically palpable, asymptomatic, and non-visible**:10**,²
  - The majority of nodule and papule events were mild to moderate and 95% resolved without treatment**:10**,²
  - Injection site granulomas were not observed in clinical trials, but have been received from post-marketing surveillance in the US and outside**:10**,²

**References:**

8. Sculptra® *Aesthetic Prescribing Information; 2012.*
10. Patients experiencing multiple episodes of a given adverse event were counted once within each Medical Dictionary for Regulatory Activities term.²

© 2014 A division of Valeant Pharmaceuticals North America LLC. SCUCA 14-020